Galmed Pharmaceuticals Ltd. (GLMD) is up over 46% at $5.67 in pre-market trading Tuesday, on news of the company regaining compliance with the minimum bid price requirement outlined in the Nasdaq Listing Rule. The company was previously notified by Nasdaq on September 19, 2023, that its ordinary shares had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Allarity Therapeutics Inc. (ALLR) announced that two patients enrolled in a phase II clinical trial of its investigational drug Stenoparib for advanced, recurrent ovarian cancer have now exceeded one year on therapy. This remarkably lengthy treatment period highlights the potential of Stenoparib to provide durable clinical benefit, even in heavily pre-treated ovarian cancer patients who have limited treatment options, noted the company. Shares are up over 30% at $4.40.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.